Fentanyl buccal - BioDelivery Sciences

Drug Profile

Fentanyl buccal - BioDelivery Sciences

Alternative Names: BEMA-Fentanyl; Breakyl; Fentanyl buccal soluble film; Fentanyl transmucosal - BioDelivery Sciences; Onsolis; Painkyl

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QLT USA
  • Developer BioDelivery Sciences International; Meda; TTY Biopharm
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cancer pain

Most Recent Events

  • 14 Dec 2017 BioDelivery Sciences International receives the required 90-day notice from Collegium Pharmaceutical regarding termination of the license and development agreement for fentanyl buccal soluble film
  • 09 Aug 2017 BioDelivery Sciences plans to launch fentanyl buccal in USA in the first half of 2018
  • 15 May 2017 BioDelivery Science International intends to submit a regulatory application with US FDA to qualify new manufacturer Collegium Pharmaceutical in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top